LEADERSHIP.
EMPOWERMENT.
DEVELOPMENT.

2022 Agenda

Friday, April 29, 2022

Target Audience

This activity has been designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma
  • Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma
  • Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data
  • Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL
  • Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma

Friday, April 29

Interprofessional Session

Presenter

8:00 – 8:15 AM
Welcome and Introductions
8:15 – 9:15 AM

Palliative Care

9:15 – 10:15 AM
Psychosocial support – anxiety, depression in lymphoma patients
10:15 – 10:30 AM
Survivorship
10:30 – 11:00 AM
Break/Virtual Exhibits
11:00 – 11:45 AM
Supportive Therapies for Novel Oral Therapies
11:45 – 12:30 PM
Multidisciplinary Approach to care management
12:30 – 12:45 PM

Q&A

12:45 – 12:55 PM
Session Wrap-Up and Closing

General Session Day 1

Friday, April 29

General Session

Presenter

1:00 – 1:10 PM
Welcome and Introductions
Moderator:

1:10 – 3:00 PM

Mini Symposium on Follicular Lymphoma (FL)
Moderator

1:10 – 1:15 PM Pre-session ARS

1:15 – 1:35 PM: Biology of FL

  • Biology of transformation
  • Pathology

1:35 – 1:55 PM: Targeted agents in FL – How to choose?

  • Small molecule inhibitors
  • Oral agents

1:55 – 2:15 PM: Immunotherapy for FL (Caron Jacobson?)

  • CAR T-cells
  • Emerging bispecifics

2:15 – 2:35 PM: Management of the FL patient in the COVID era

  • Role of bendamustine
  • Is maintenance therapy still appropriate?

2:35 – 3:00 PM: Panel discussion with speakers, Q&A, and post-session ARS



Robert Kridel




Tycel Phillips (Michigan)




Sairah Ahmed (MDACC)




Leo Gordon (NU)
3:00 – 3:30 PM
Break & Exhibits
3:30 – 4:55 PM
Mini Symposium on Mantle Cell Lymphoma (MCL)
Moderator

3:30 – 3:50 PM: Case presentations – how would you treat? (with ARS)

  • Newly diagnosed MCL and potential role of auto SCT
  • Relapsed MCL – suboptimal response to a BTK inhibitor…do you continue treating with the BTK inhibitor or proceed to CAR T-cell therapy
  • p53 mutated MCL

3:50 – 4:40 PM: Debate – role of auto transplant

  • 3:50: Consolidative auto SCT in MCL – pro (Tim Fenske)
  • 4:10: Consolidative auto SCT in MCL – con (John Leonard)
  • 4:30: Panel discussion, audience Q&A, and rebuttals

4:40 – 4:55 PM: Sequencing of therapies in R/R MCL

  • CAR T-cell patient selection criteria
  • Optimal timing of CAR T-cell therapy


Reem Karmali









Kami Maddocks
4:55 – 5:00 PM
General Session Wrap Up and Summary
IUCLS Chairs

Friday, April 30, 2022

General Session Day 2

Saturday, April 30

General Session

Presenter

8:00 – 8:10 AM
Welcome and Introductions
Moderators:
8:10 – 10:00 AM
Mini Symposium on Hodgkin Lymphoma (HL)

8:10 – 8:15 AM: Pre-session ARS

8:15 – 8:35 AM: Impact of the immune landscape on Hodgkin lymphoma prognosis and treatment (Margaret Shipp or someone in her lab?)

8:35 – 8:55 AM: Treatment of 1st relapsed HL (Vaishalee Kenkre)

8:55 – 9:15 AM: Relapse after auto SCT, brentuximab vedotin, and checkpoint inhibitors – the next frontier

  • Allo SCT
  • CAR T-cells
  • Promising investigational agents on the horizon
  • ARS on what audience would choose

9:15 – 9:35 AM: Post-acute (years 1-10) outcomes in HL (Lindsay Morton)

9:35 – 10:00 AM: Speaker panel discussion, audience Q&A, and post-session ARS







Christian Steidl (BCA)


Vaishalee Kenkre (Wisconsin)








Lindsay Morton
10:00 – 10:15 AM
Break & Virtual Exhibits
10:15 – 11:35 AM
Primary and Secondary CNS Lymphoma
Moderator:

10:15 – 10:20 AM: Pre-session ARS

10:20 – 10:40 AM Primary CNS lymphoma – focus on consolidation (Tracy Batchelor?)

  • Whole brain vs auto SCT vs chemotherapy

10:40 – 11:10 AM CNS lymphoma prophylaxis

11:10 – 11:30 AM: Treatment of relapsed primary and secondary CNS lymphoma (Mark Roschewski?)

  • CAR T-cell therapy
  • Intrathecal rituximab

11:30 – 11:35 AM: Audience Q&A



Tracy Batchelor


Craig Portell


Andres Ferreri
11:35 AM – 12:35 PM
Keynote Symposium: CLL

11:35 AM – 12:35 PM: Limited duration treatment of relapsed CLL: are we there yet?

  • CAR T-cells
  • Richter’s transformation
  • Other aggressive subtypes
12:35 – 1:00 PM
Lunch & Exhibits
1:00 – 2:50 PM
Mini Symposium on Aggressive Lymphoma
Moderator:

1:00 – 1:05 PM: Pre-session ARS

1:05 – 1:25 PM: HBGL NOS: how to differentiate and what to do? (David Scott)

1:25 – 1:45 PM: Prognostication and treatment of Burkitt lymphoma in the modern era (Adam Olszewski)

1:45 – 2:05 PM: When is R-CHOP not the preferred regimen for newly diagnosed DLBCL?

  • Include polatuzumab data
  • Older patients

2:05 – 2:25 PM: How to sequence non-CAR T-cell therapy for relapsed DLBCL

2:25 – 2:50 PM: Speaker panel discussion, audience Q&A, and post-session ARS






David Scott


Adam Olszewski




Laurie Sehn


Dan Landsburg

2:50 – 4:15 PM

Mini Symposium on Next Generation Cellular and Targeted Therapies

2:50 – 2:55 PM Pre-session ARS

2:55 – 3:15 PM Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies

3:15 –3:35 PM New CART Constructs: What is on the Horizon? (Tonya Siddiqui)

3:35 – 3:55 PM Bispecific Antibodies (Martin Hutching)

3:55 – 4:20 PM: Speaker panel discussion, audience Q&A, and post-session ARS

Jeremy Abramson

Tonya Siddiqui


Martin Hutching
4:20 – 4:35 PM
Summary and Best of IUCLS
IUCLS Chairs
4:35 PM
Adjourn